Fig. 2.

Meta-analysis to investigate the effect of short- versus long-acting G-CSFs on the incidence of chemotherapy dose reductions and dose delays in non-RCTs.^a i Meta-analysis for chemotherapy dose reductions in non-RCTs using a fixed-effect model, and ii meta-analysis for chemotherapy dose delays in non-RCTs using a fixed-effect model. ^aThe dotted square indicates studies in which G-CSF administration adhered to label recommendations (≥ 7 days of treatment). CI confidence interval, G-CSF granulocyte colony-stimulating factor, I² Chi squared, RCT randomized controlled trial, RR relative risk